FP
OMGA

Flagship Pioneering’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Flagship Pioneering’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-29,225,579
Closed -$21.8M – 5
2024
Q4 		$21.8M Hold
29,225,579
– – 6.52% 4
2024
Q3 		$35.7M Hold
29,225,579
– – 6.02% 4
2024
Q2 		$60.5M Hold
29,225,579
– – 7.17% 4
2024
Q1 		$107M Hold
29,225,579
– – 7% 3
2023
Q4 		$88M Hold
29,225,579
– – 6.64% 3
2023
Q3 		$62.8M Hold
29,225,579
– – 4.56% 4
2023
Q2 		$164M Hold
29,225,579
– – 7.3% 3
2023
Q1 		$176M Buy
29,225,579
+3,323,310
+13% +$23.1M 6.85% 2
2022
Q4 		$293M Hold
25,902,269
– – 9.37% 2
2022
Q3 		$140M Hold
25,902,269
– – 5.91% 4
2022
Q2 		$98.4M Hold
25,902,269
– – 3.71% 5
2022
Q1 		$162M Hold
25,902,269
– – 3.8% 5
2021
Q4 		$293M Hold
25,902,269
– – 4.54% 4
2021
Q3 		$488M Buy
+25,902,269
New +$497M 5.11% 4

Other funds holding OMGA

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $6.82B AUM 17.15% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Flagship Pioneering's OMGA Position: Q1 2025 in Review

Flagship Pioneering sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q1 2025, closing a stake of 29,225,579 shares — an estimated $21.8M sold.

Flagship Pioneering first reported a position in OMGA in Q3 2021 and held it in 14 quarters. The position peaked at $488M in Q3 2021. 4 funds tracked by Wall St. Rank hold OMGA as of Q1 2025.

  • Flagship Pioneering reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Flagship Pioneering sold 29,225,579 Omega Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $21.8M.
  • Flagship Pioneering first reported a position in Omega Therapeutics, Inc. Common Stock in Q3 2021 and held it in 14 quarters.
  • Flagship Pioneering's Omega Therapeutics, Inc. Common Stock position peaked at $488M in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Flagship Pioneering's 13F filing for Q1 2025, filed 15 May 2025.